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ABSTRACT
Mesenchymal stem cells (MSC) have been derived from different cultured human tissues, including bone marrow, adipose tissue, amniotic
fluid and umbilical cord blood. Only recently it was suggested that MSC descended from perivascular cells, the latter being defined as
CD146 neuro-glial proteoglycan (NG)2 platelet-derived growth factor-R ALP CD34– CD45– von Willebrand factor (vWF)– CD144–.
Herein we studied the properties of perivascular cells from a novel source, the foetal human umbilical cord (HUC) collected from pre-term
newborns. By immunohistochemistry and flow cytometry we show that pre-term/foetal HUCs contain more perivascular cells than their full-
term counterparts (2.5% versus 0.15%). Moreover, foetal HUC perivascular cells (HUCPC) express the embryonic cell markers specific
embryonic antigen-4, Runx1 and Oct-4 and can be cultured over the long term. To further confirm the MSC identity of these cultured
perivascular cells, we also showed their expression at different passages of antigens that typify MSC. The multilineage differentiative capac-
ity of HUCPC into osteogenic, adipogenic and myogenic cell lineages was demonstrated in culture. In the perspective of a therapeutic appli-
cation in chronic lung disease of pre-term newborns, we demonstrated the in vitro ability of HUCPC to migrate towards an alveolar type II
cell line damaged with bleomycin, an anti-cancer agent with known pulmonary toxicity. The secretory profile exhibited by foetal HUCPC in
the migration assay suggested a paracrine effect that could be exploited in various clinical conditions including lung disorders.
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Introduction
Mesenchymal stem cells (MSC) are multipotent precursors able to
differentiate into various mesodermal cell types [1]. These cells,
for which a unique set of markers – that should allow their direct
purification – is still missing, have been isolated retrospectively
from bone marrow and several other tissues, by adherence to
culture plastic.
A close resemblance between MSC and pericytes has been
uncovered, suggesting a perivascular origin for the former [2–6]
and suggesting why MSC can be isolated from all tissues.
Pericytes, also known as mural cells or Rouget cells [7–8] are
closely adherent to endothelial cells in capillaries and microves-
sels. Pericytes have been identified in some tissues [9–12] based
on the expression of different antigens and only in a very recent
work did some of us validate a set of markers to precisely localize
and isolate pericytes/perivascular cells in human foetal and adult
organs including muscle, pancreas, bone marrow, adipose tissue
and placenta. Moreover, we demonstrated for the first time that
these cells can give rise to MSC in culture, thus the elusive MSC
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[13]. The human perivascular cell is defined by expression of NG2,
a proteoglycan expressed during vascular morphogenesis
[14–15], CD146 (aka S-endo1, Mel-CAM, Muc18 or gicerin), an
endothelial cell antigen also expressed at the surface of pericytes
[16–18] and platelet-derived growth factor (PDGF)-R, a tyrosine-
protein kinase implicated in the control of cell proliferation, sur-
vival and migration.
Human umbilical cord (HUC) has been mainly used as a source
of endothelial cells (HUVEC) [19–20] and of mesenchymal stromal
cells derived from the Wharton’s jelly (WJ) [21–22].
In this study, we localized perivascular cells present in the
human full-term umbilical cord and, at a higher frequency, in the
foetal (pre-term) cord. We isolated, characterized and expanded
these cells in culture and we show that they exhibit the features of
MSC, being able to differentiate into mesodermal cell lineages and
to migrate towards a damaged tissue. These properties are partic-
ularly relevant in view of cellular therapy applications in pre-term
newborns, for instance those who are at high risk for chronic lung
disease or bronchopulmonary dysplasia (BPD). In fact, although
the survival of premature newborns has improved and refinement
in neonatal intensive care has modified the outcome of BPD,
attempts to prevent or treat this disease are still disappointing.
This context prompted us to envision pre-term HUC perivascular
cells as novel therapeutic stem cells for treating lung disorders in
premature newborns.
Materials and methods
Isolation and culture of human umbilical cord
perivascular cells
HUCs from pre-term (23–32 weeks of gestation; n  24) and full-term 
(n  7) newborns were obtained after informed consent from 31 preg-
nant women. HUC (median length 14 cm, range 8–24) were dissected
longitudinally to expose the WJ, the vein and the two arteries and the
ends of the cords were sutured in order not to digest the internal walls
of the vessels (Fig. 1A). The samples were digested with 1 mg/ml colla-
genase A (Roche Diagnostics GmbH; Mannheim, Germany) at 37C until
perivascular regions were dissociated, for a maximum of 18 hrs. The
non-digested material was discarded and the cell suspension was col-
lected, diluted with phosphate-buffered saline (PBS; Gibco, Grand Island,
NY, USA) to reduce the viscosity and centrifuged at 1400 rpm for 10 min.
The pellet was resuspended and the HUC perivascular cells (HUCPC)
were seeded in EGM2 medium (Lonza, Walkersville, MD, USA) on a pre-
coated gelatine layer (Sigma-Aldrich; St. Louis, MO, USA). After 1 week,
the medium was replaced with DMEM high-glucose (Invitrogen,
Carlsdad, CA, USA), supplemented with 20% foetal bovine serum (FBS;
Biochrom, AG, Berlin, Germany) and 1% penicillin/streptomycin (P/S,
Sigma-Aldrich) and maintained in long-term culture at 37C in a humidi-
fied atmosphere containing 5% CO2. Adherent cells, 80% confluent, were
passaged by treatment with trypsin-ethylenediaminetetraacetic acid
(Gibco), and split 1:3 in uncoated plates in the same culture conditions.
Medium was changed every 3 days.
Immunohistochemistry
Fresh pre- and full-term HUC were gradually frozen by immersion in isopen-
tane (Merck Group, Frankfurter, Germany) cooled in liquid nitrogen and
embedded in tissue freezing medium (Triangle Biomedical Sciences,
Durham, NC, USA). Seven micrometre sections were cut on a cryostat
(Thermo Scientific Microm, Walldorf, Germany) and fixed for 5 min. with
50% acetone (VWR International, West Chester, PA, USA) and 50%
methanol (Fischer Scientific, Pittsburgh, PA, USA) or for 10 min. in 4%
paraformaldehyde (Sigma-Aldrich). Sections were dried for 5 min. at room
temperature (RT), washed three times for 5 min. in PBS and blocked with 5%
goat serum (Gibco) in PBS for 1 hr at RT. Sections were incubated with
uncoupled primary antibodies overnight at 4C, or 2 hrs at RT in the case of
directly coupled antibodies. After rinsing, sections were incubated for 
1 hr at RT with a biotinylated secondary antibody, then with fluorochrome-
coupled streptavidin, both diluted in 5% goat serum in PBS. The following
uncoupled anti-human primary antibodies were used: anti-CD146 (BD,
Becton Dickinson, San Jose, CA, USA; 1:100), anti-CD31 (DAKO, Glostrup,
Denmark, 1:100), CD34–fluorescein isothiocyanate (FITC) (DAKO, 1:50) and
anti-CD105 (Invitrogen, 1:50). The coupled antibodies were: biotinylated
anti-CD144 (BD, 1:100), -smooth muscle actin-FITC (SMA, Sigma-Aldrich,
1:100) and biotinylated anti-CD146 (Miltenyi Biotec, Gladbach, Germany,
1:11). Streptavidin-Cy3 (Sigma-Aldrich, 1:500) and streptavidin-Cy5 (CyDye,
1:500) were used in conjunction with biotinylated antibodies. Uncoupled
Ulex europaeus agglutinin I (UEA-I; Vector Laboratories, Burlingame, CA,
USA; 1:100) was also used. Nuclei were stained with DAPI (4, 6-diamino-2-
phenylindole dihydrochloride; Molecular Probes, Inc., Eugene, OR, USA;
1:2000) for 5 min. at RT. An isotype-matched negative control was per-
formed with each immunostaining where the primary antibody was omitted
and replaced by PBS supplemented with 5% of goat serum. Slides were
mounted in glycerol-PBS (1:1, Sigma-Aldrich) and observed on an epifluo-
rescence microscope (Nikon Eclipse TE 2000-U, Nikon Corporation, Tokyo,
Japan). Alternatively, sections were analysed on an Olympus Fluoview 1000
confocal microscope equipped with 100 oil immersion optics.
RNA isolation and RT-PCR analysis
Total RNA was extracted from 3  105 to 1  106 foetal HUCPC using the
RNeasy Mini Kit (Qiagen AG, Hilden, Germany). The total RNA was eluted in a
final volume of 40 	l, and its quality, integrity and size distribution was assessed
by optic density (absorbance at 260/280 nm and ratio of 
1.8). Four ng of
cDNA were used for each PCR assay. The primers used for PCR are listed in
Table 1. Positive controls were obtained from the corresponding foetal tissues.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a
housekeeping gene. The primers were constructed on the basis of pub-
lished human sequences, and selected using version 1.5 of the Primer
Express software available from Applied Biosystems (Applied Biosystems,
Inc., Foster City, CA, USA). Each set of oligonucleotides was designed to
span two different exons. The samples were loaded on 1% agarose gels.
Flow cytometry analysis
HUCPC isolated from foetal and term cords were characterized by flow cytom-
etry before and during culture. Cells were washed in PBS for 20 min. at RT
and incubated in the dark with the following directly coupled mouse 
anti-human antibodies: CD13-phycoecythrin (PE) (BD), CD34-PE (BD), CD44-
FITC (BD), CD45-PC7 (Beckman Coulter, Fullerton, CA, USA), CD56-PE
798 © 2011 The Authors
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(Chemicon, Temecula, CA, USA), CD73-PE (BD), CD90-PE (Chemicon),
CD105-PE (ImmunoTools, Friesoythe, Germany), CD133-PE (Miltenyi Biotec),
CD146-PE/FITC (BioCytex, Marseille, France), -SMA FITC (Sigma-Aldrich),
NG2-PE (Beckman Coulter), PDGF-R PE (BD), human leukocyte antigen
(HLA)-ABC-FITC (BD), HLA-DR (BD), CD144-FITC (VE-cadherin; Bender
MedSystem, Burlingame, CA, USA). The isotype-matched immunoglobulins
IgG1 PE-FITC (Chemicon), IgG1-PC7 (Beckman Coulter) and IgG1-APC (BD)
were used as negative controls under the same conditions. After staining the
cells were washed once with PBS containing 0.1% bovine serum albumin. At
least 50,000 events were acquired with a Cytomics FC500 flow cytometer
(Beckman Coulter) and plots were generated using the CXP analysis software.
Immunocytochemistry
Foetal HUCPC were first fixed with cold methanol/acetone (1:1) for 2 min.
When necessary, cells were permeabilized with 0.1% Triton X-100 
(10 min.), then washed in PBS (Gibco). Non-specific binding sites were
blocked with PBS containing 2% bovine serum albumin (Sigma-Aldrich)
for 20 min. at RT. Cells were incubated with directly coupled anti-human
antibodies: CD146-FITC/PE (ByoCytex, Marseille, France; 1:20), NG2-PE
(Immunotech, Marseille, France; 1:50), CD34-FITC (DAKO, 1:50), CD144-
FITC (Bender MedSystems, 1:25), -SMA-FITC (Sigma-Aldrich, 1:100),
PDGF-R PE (BD, 1:20) for 1 hr at RT. Uncoupled mouse anti-human anti-
bodies were: CD133 (Miltenyi, Miltenyi Biotec; 1:50), vWF (DAKO; 1:40),
stage-specific embryonic antigen-4 (SSEA-4; Chemicon, 1:25), pro-surfac-
tant protein C (Chemicon, 1:100) and rabbit polyclonal antibody anti-
human Oct-4 (Chemicon, 1:50). Uncoupled UEA- I (Vector, 1:100) was also
used. After staining with primary unconjugated antibodies, cells were incu-
bated with FITC-conjugated goat antimouse antibody (Exalpha
Biolologicals Inc., Shirley, MA, USA. 1:300), with PE-conjugated goat anti-
mouse antibody (Exalpha, 1:300), or with FITC-conjugated goat anti-rabbit
antibody (Vector, 1:300) for 1 hr at RT. Nuclear counterstaining with DAPI
(Roche Diagnostic Corporation, Indianapolis, IN, USA) was performed for
Fig. 1 Isolation, culture and immunocytochemical characterization of HUCPC. The dissection under sterile condition of foetal and full-term cords was
performed to expose the WJ, the vein and arteries (A). After the in vitro expansion of foetal HUCPC (B) the cells showed a homogeneous morphology
(B I, 20) and form ‘round bottom’ colonies (B II, 40). (C) The growth rate of foetal HUCPC, calculated as cumulative number of population dou-
blings (CPD), was fastest during weeks 4–10 of expansion. (D) The immunocytochemistry analysis at passage 3 of the culture showed that foetal HUCPC
are positive for CD146 (I, II, IV: red; III: green) and co-expressed NG2 (I: green), -SMA (II: green), PDGF-R (III: red) and SSEA-4 (IV: green).
Moreover, the SSEA-4 cells (V: red) expressed also Oct-4 (V: green). All the cells (I–V) were stained with DAPI (blue). Magnification: I–II 40; III–V
60. All the slides were analysed using a Video Confocal Microscope (ViCo-Eclipse 80i, Nikon) equipped with a Plan Fluor 40 1.30 DIC H/N2 Oil objec-
tive or with a Plan Apo VC 60/1.40 oil DIC N2 (Nikon).
J. Cell. Mol. Med. Vol 15, No 4, 2011
799© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
15 min. at RT. An isotype-matched negative control was performed with
each immunostaining where the primary antibody was omitted and replaced
by PBS supplemented with 2% of FBS. All slides were mounted with
DakoCytomation Fluorescent Mounting Medium (DakoCytomation, Glostrup,
Denmark) and the cells were analysed using a video confocal microscope
(ViCo-Eclipse 80i, Nikon, Tokyo, Japan) equipped with Plan Fluor 40 1.30
DIC H/N2 and Plan Apo VC 60/1.40 DIC N2 oil objectives (Nikon).
Photographs were acquired with a CCD cooled interline-transfer FireWire
camera (Nikon) and processed using Media Cybernetics Image Pro Plus
(Media Cybernetics Inc., Bethesda, MD USA).
Pictures of the migration assay were taken with a Plan Fluor (Nikon)
100/1.30 oil numeric aperture objective and a DS camera control 
(DS-5M, Nikon). Images were captured using a Nikon Digital Slide DS-L1
(Nikon), merged and analysed with Adobe Photoshop 5.5 software
(Microsoft Corporation, Washington, DC, USA).
Cell lineage differentiation
Foetal HUCPC at passage 3 were differentiated into adipogenic, osteogenic
and myogenic cell lineages in different media. To promote adipogenic dif-
ferentiation, HUCPC were plated at 2.1  104 cells/cm2 in human MSC
Adipogenic Induction (catalogue number PT-3102B/PT-4135) and
Maintenance (catalogue number PT-3102A/PT-4122) Medium (Lonza). At
confluence, three cycles of induction/maintenance were performed, then
HUCPC were cultured for seven more days in supplemented adipogenic
differentiation maintenance medium (Lonza), replacing the medium every
2–3 days. The cells were stained with Oil Red O solution (Sigma-Aldrich)
to detect lipid vacuoles. For osteogenic differentiation, 3.1  103 cells/cm2
were grown for 3 weeks in human MSC osteogenic medium (catalogue
number PT-3924/PT4120 Lonza). Induced cells were first fixed with 70%
ethylic alcohol for 1 hr and then stained with Alizarin Red S 40 mM (Sigma-
Aldrich) for 10 min. to detect the presence of calcium deposits.
Images of colorimetric assays were acquired on a Nikon Eclipse TS100
microscope equipped with 40/0.55 Ph1 ADL and 20/0.40 Ph1 ADL
objectives and photographs were taken with a Nikon Digital Slide DS-L1.
For muscle differentiation, a mouse skeletal muscle cell line (G-7 line)
was purchased from ATCC (CRL-1447, Manassas, VA, USA) and was used
for the co-culture experiments to promote myotube formation.
First, the G-7 cells were seeded on a cover glass in a defined medium
including DMEM low glucose, 20% FBS (Biochrom), 10% horse serum
(Biodesigned International, Saco, ME, USA), 0.5% chick embryo extract
(US Biological, Swampscott, MA, USA) and 1% P/S (Sigma-Aldrich). After
12 hrs, a defined medium containing 5-azacytidine (3 	M) was added and
replaced 24 hrs later with a 5-azacytidine-free defined medium.
Afterwards, 50  103 foetal HUCPC were first stained with the fluorescent
dye PKH26, using PKH26 Red Fluorescent Cell Linker Kit (Sigma-Aldrich)
following manufacturer’s instructions and then co-cultured for at least 
21 days with the G-7 cells. A parallel co-culture was performed with a non-
damaged G-7 cell line under the same culture conditions as control.
For muscle differentiation the expression of specific myogenic markers
such as spectrin (Novocastra, Newcastle, UK) and dystrofin (Novocastra)
was analysed by immunocytochemistry. The antibodies strongly reacted
with the domain of human spectrin and dystrophin, while no reactivity with
mouse tissue was observed. All slides were analysed on a video confocal
microscope. For all the differentiation cultures negative controls were set
up replacing the specific lineage induction media with the standard expan-
sion media.
Migration assay
The alveolar type II epithelial rat cell line (ATII) (CRL-2300, ATCC) was cul-
tured in Ham’s F12 medium (Invitrogen), 10 	g/ml bovine pituitary extract
(Gibco), 2.5 ng/ml insulin-like growth factor-I (PeproTech EC Ltd., London,
England), 2.5 ng/ml epidermal growth factor (PeproTech), 10% FBS
(Biochrom) and insulin-transferrin-selenium (Gibco).
For the migration assay, 1.5  104/cm2 ATII cells were first grown on
a pre-coated glass slide (0.01% poly-L-lysine for 30 min., Sigma-Aldrich)
in a humidified atmosphere at 37C 5% CO2 (Fig. 6B, I). The culture
medium was replaced once until 80% cell confluence was reached.
Different concentrations of bleomycin (5–50 	g/ml) (Aventis, Paris,
Table 1 Sequences of human-specific primers used for PCR analysis of foetal HUCPC
Primers
CD45 F -catgtactgctcctgataagac R- gcctacacttgacatgcatac
CD146 F -aaggcaacctcagccatgtcg R- ctcgactccacagtctgggac
CD34 F -catcactggctatttcctgatg R- agccgaatgtgtaaaggacag
CD31 F -gaagtacggatctatgattcag R- gtgagtcacttgaatggtgca
MyoD F -cagcgaatgcagctctcaca R- agttgggcatggtttcatctg
Myf5 F -cagtcctgtctggtccagaa R- ggaactagaagcccctggag
Pro-surfactant protein C F -tgaaacgccttcttatcgtgg R- cctgcagag age att ccatct
Oct-4 F -acatgtgtaagctgcggcc R- gttgtgcatagtcgclgcttg
Runx1 F -tcaclgtgatggctggcaat R- ctgcatctgactctgaggctga
Rex1 F -aaacatgagccagcaactgaag R- agaaatcatcccctccgagag
Sox-2 F -accagaaaaacagcccgga R- tcatgagcgtctlggttttcc
CD144 F -tctctgtttgttgaggaccc R -aagtggtagaaaggctgctg
GAPDH F -gcttgtcatcaatggaaatccc R- tccacacccatgacgaacatg
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France) and times of exposure (12–72 hrs) were tested on ATII cells to
optimize a subletal damage (data not shown). The concentration of 10 	g/ml
bleomycin was eventually chosen. The ATII cell line was damaged for 40 hrs,
and then the medium was replaced. 24 hrs after damage, foetal HUCPC
were first stained with the fluorescent dye PKH26, a Red Fluorescent Cell
Linker Kit (Sigma-Aldrich) following manufacturer’s instructions, then co-
cultured (5  104 cells/well) in transwells (8.0 	m pore size) with the
damaged cell line. A parallel co-culture was performed under the same
conditions with non-damaged ATII cells as a control. Migration of the
PKH26 cells was evaluated every day with the inverted fluorescence
microscope. After 14 days, the samples were fixed with cold methanol/ace-
tone (1:1) for 2 min. and migratory HUCPC in contact with the damaged
alveolar cell layer were stained for pro-surfactant protein C (Chemicon,
1:100), CD146 (BioCytex, 1:20), anti- SMA FITC (Sigma-Aldrich, 1:100)
and then with FITC-conjugated goat anti-rabbit antibody (Exalpha, 1:300).
In addition to exclude the possibility that migratory activity of HUCPC 
was caused by different ATII cell density, several cell concentrations (from 
5  103 to 20  103) of undamaged ATII were tested as an additional con-
trol and co-cultured with PKH26 HUCPC.
Chemotaxis assay
Chemotactic responses were measured by a modified Boyden chamber
assay, using a 24-well chamber with polycarbonate filters (8.0 	m pore size)
coated with Matrigel basement membrane matrix (BioCoat Invasion Assay,
BD). The lower wells were filled with conditioned medium collected from
damaged ATII cells and covered by the chemotaxis filter. The HUCPC (n  4)
were trypsinized, counted, and the upper wells were filled with 5  104
HUCPC in DMEM. After 24 hrs incubation, the filter was carefully removed
and non-migrated cells on the upper side eliminated by rinsing with cold PBS
and scraping over a rubber wiper. The migrated cells on the lower side of the
filter were fixed with cold acetone/methanol 1:1 (v:v) for 3 min. and stained
with DAPI. In the controls, the lower wells were filled with medium collected
from undamaged ATII cells. HUCPC that migrated through the filter pores
and attached underneath the membrane were counted by microscopy. The
number of migrated cells in control and stimulated wells was counted at
100 magnification. Results were expressed as chemotactic index, deter-
mined as the average number of migrated cells in stimulated wells divided
by average number of migrated cells in control wells.
ELISA
A quantitative sandwich enzyme immunoassay technique (Quantikine,
R&D Systems, Minneapolis, MN, USA) was used following the manufac-
turer’s instructions to evaluate the production of soluble factors by HUCPC.
During the co-culture of foetal PKH26 HUCPC with damaged ATII
epithelial cells, supernatants from six independent experiments were col-
lected at different times (24, 48, 72 hrs after damage) and immediately
stored at –20C until evaluation. As controls, supernatants were collected
from (1) a co-culture of PKH26 HUCPC with non-damaged ATII cells; (2)
damaged ATII cultured cells; (3) cultured HUCPC. The evaluated soluble
factors were: keratinocyte growth factor (KGF), PDGF-BB and vascular
endothelial growth factor (VEGF). The optical density of each sample was
determined using a microplate reader set to 450 nm (Genios Plus, TECAN,
Salzburg, Austria). Data were analysed using Magellan Software and
expressed as mean picograms of the secreted factors per millilitre at the
time of harvest.
Statistical analysis
The Wilcoxon-based method was used to determine the significance of dif-
ferences between independent groups. Statistical significance level was
defined as P  0.05.
Results
(1) Immunohistochemical detection of perivascular
cells in foetal and term umbilical cords
Immunohistochemistry was used to detect the presence of
perivascular cells in different umbilical cord compartments includ-
ing WJ, vein and arteries. To this end, we examined two foetal and
three term cords. Perivascular smooth muscle cells surrounding
the big vessels present in the foetal cord co-express CD146 and
SMA. Only in the foetal cord we could also detect microvessels,
arteriole and veinule, with diameters ranging from 10 to 100 	m
(Fig. 2A). Perivascular cells presented the same phenotype in
small and big vessels and they did not express the known
endothelial cell markers CD144, CD34, CD31, UEA-1 receptor.
The distribution of CD146 and -SMA in umbilical cords at
term was slightly different. First, no small blood vessels were
found in term cords. The 2 arteries present numerous perivascu-
lar cell layers, all co-expressing CD146 and -SMA. The vein had
a particular phenotype since only rare CD146high -SMA cells
were observed within the vascular wall, especially at the distal
periphery (Fig. 2C). All other venous perivascular cells strongly
expressed -SMA but not CD146.
In both foetal and term WJ, no cells expressing CD146, CD144,
CD34, CD31 or the UEA-1 receptor were found. WJ cells express
CD105 (Fig. 2B and D) and -SMA (not shown). The frequency of
these CD105 cells was much lower in term cords than in the
foetal counterpart cords.
(2) Morphology, phenotype and molecular profile
of HUCPC
The digestion procedure yielded an average of 1–8.2  106 cells per
HUC depending on the length of HUC harvested, which ranged from
8 to 24 cm. Foetal and term HUC were then processed before cul-
ture to characterize perivascular cells by flow cytometry. CD56
cells, as well as hematopoietic cells (CD45) were initially gated out
[23]. Perivascular cells were identified by high CD146 expression
and lack of CD34, the latter to ascertain the absence of endothelial
cells. Interestingly, the perivascular cell population (CD146 CD34–
CD45– CD56–) was observed mainly in foetal samples, rather than
in term cords (2.5% versus 0.15%), confirming immunohistochem-
istry observations. These cells clearly expressed PDGF-R. All of
the results of immunocytochemistry are reported in Table 2.
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Further experimental strategy was focused on foetal cord cell
isolation, since it is richer in perivascular cells. Our cell isolation
approach consisted of a strategy including the ligation of the ends
of cords and appropriate culture conditions that led us to exclude
as much as possible the endothelial contamination from the begin-
ning and to selectively favour the growth of the perivascular cells.
These cells, maintained in long-term culture, exhibited a spindle
shape (Fig. 1B, I) and formed ‘round bottom’ colonies (Fig. 1B, II).
The growth rate was calculated as cumulative number of popula-
tion doublings during weeks [24]. Growth was slow in the first 
3 weeks and the fastest rate was during weeks 4–10 (Fig. 1C).
At passage 3, cultured cells were detached by trypsin and
characterized by flow cytometry. Foetal HUCPC were positive for
CD90 (median 100%, range 97–100), CD73 (84%, 74–93),
CD105 (86%, 30–100), CD44 (90%, 80–99) and HLA-ABC (97%,
60–100). They also expressed CD146 (63%, 23–81), NG2 (19%,
9–25), PDGF-R, (93%, 85–95), -SMA (60%, 40–80), but not
CD34, CD45 and CD56. Moreover, foetal HUCPC were negative
for CD133, CD144 and HLA-DR expression, confirming their
MSC-like profile (Fig. 3). Comparable percentages were found at
passage 6.
As illustrated by Figure 1D (I), CD146 cultured perivascular
cells were also positive for NG2, -SMA (Fig. 1D, II) and PDGF-R
(Fig. 1D, III) expression. In contrast, perivascular cells did not
express endothelial cell markers such as CD144, CD34, CD133
Fig. 2 Localization of HUCPC
in sections of foetal and full-
term HUC by immunohisto-
chemistry. The presence of
HUCPC co-expressing CD146
(red) and -SMA (green) was
also detected around microves-
sels of foetal HUC (A; magni-
fication 400). Cells co-
expressing CD146 and -SMA
were identified with a low 
frequency in the peripheral
vascular wall of full-term HUC
(C; magnification 200). WJ
cells expressing CD105 (red)
were much lower in full-term
cords (D; magnification 200)
than in the foetal cords sec-
tions (B; magnification 200).
Cell markers Foetal cord (%) Term cord (%)
CD146 CD34CD45 CD56 7.44 (13.94) 0.93 (1.70)
CD146 PDGF-R 11.58 (6.12) 0.33 (0.40)
SMA NG2 0.34 (0.39) 0.67 (1.49)
SMA 56.20 (24.49) 53.72 (40.11)
NG2 17.88 (27.50) 13.94 (22.42)
CD144 11.13 (11.31) 6.26 (5.88)
PDGFR 12.92 (14.59) 3.93 (6.38)
Table 2 Comparison of the expression of surface markers in foetal -
and full-term HUCPC after the isolation and before the cell expansion
(human foetal umbilical cords n  24, human term umbilical cords 
n  7). The results are expressed as mean  S.D.
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and the UEA-I receptor (Table 3). Moreover, HUCPC co-expressed
the embryonic stem cell markers SSEA-4 and a relatively low level
of Oct-4 (Fig. 1D, IV–V).
Cultured perivascular cells were also analysed by RT-PCR for
the expression of embryonic, myogenic and endothelial cell mark-
ers, showing that foetal HUCPC express Runx1 and Oct-4 at dif-
ferent levels, which characterize the undifferentiated stem cell
state, and CD146, while they are negative for Rex1, Sox2, Myo-D,
Myf5, CD31, CD45, CD34 and CD144, thus excluding any myo-
genic and endothelial cell contamination (Fig. 4).
(3) Differentiation potential
To further explore a possible affiliation between MSC and cultured
umbilical cord perivascular cells, HUCPC were cultured under
appropriate inductive conditions promoting their differentiation
into osteogenic, adipogenic and myogenic cell lineages.
Fig. 3 Representative flow
cytometry analysis of
expanded foetal HUCPC. After
three passages of culture the
cells (n  24) were detached
with trypsin, washed and
stained with directly labelled
monoclonal antibodies (pink
histograms) or exposed to
isotype-matched non-immune
directly labelled immunoglob-
ulins (blue histograms). Foetal
HUCPC were positive for
CD146, PDGF-R, -SMA and
NG2, while were negative for
CD45, CD34 and CD56 con-
firming the main features of
perivascular cells. Moreover
they expressed the typical
mesenchymal markers such
as CD90, CD73, CD105, CD44,
HLA-ABC and they were nega-
tive for CD133, CD144 and
HLA-DR.










Pro-surfactant protein C 
Table 3 Immunocytochemical analysis of cultured foetal HUCPC.
Results are expressed as positive () or negative () cells on the
total number of counted cells.
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In osteogenic conditions, HUCPC became mineralized as indicated
by staining with the calcium-specific dye Alizarin red (Fig. 5A, I).
Under adipogenic induction, HUCPC generated lipid vacuoles and
became stainable by the triglyceride-specific dye Oil Red O (Fig. 5B, I).
Perivascular cells cultured in myogenic conditions developed into typ-
ical myotubes that co-expressed the tracking marker PKH26, human
dystrophin (Fig. 5C, I) and human spectrin (Fig. 5C, II). To strengthen
these results, all the differentiation cultures were stained also with the
non-lineage specific markers showing the absence of any other non-
specific lineage commitment.
(4) Migratory ability and proteome assay
A model of tissue damage was developed using bleomycin, an
antibiotic glycopeptide often used as an anti-cancer agent [25–27]
(Fig. 6A). A rat alveolar cell line (Fig. 6B, I) was used to study 
morphological changes induced by bleomycin (5, 10, 20 or 
50 	g/ml) at different time-points. The same area of each mono-
layer was examined under the phase-contrast microscope at time
intervals of 10, 24, 40 and 72 hrs. After a 40-hr treatment with
bleomycin at a concentration of 10 	g/ml, alveolar cells looked con-
tracted and started to lose contact with their neighbours (Fig. 6B, II).
At a concentration of 5 	g/ml, bleomycin did not induce significant
morphological changes, while at the highest concentration of
bleomycin (50 	g/ml) all cells were detached (data not shown).
Using this model of lung tissue damage, the migratory ability of
HUCPC was tested. After 14 days of culture, foetal PKH26 HUCPC
migrated towards the damaged alveolar cell layer (Fig. 6B, III–IV)
while no migration was observed in control cultures. Moreover,
additional controls showed that the undamaged ATII cells did not
promote migration of PKH26 HUCPC cells even at the similar low
density of the damaged ATII cells. For determining whether soluble
factors released from damaged ATII cells could initiate HUCPC
migration, a modified Boyden chamber assay was used testing the
chemotactic activity of damaged versus undamaged ATII condi-
tioned media. The mean (S.D.) of chemotactic index, resulting
from four independent experiments in duplicate, was 6.86 (1.46).
To test the capacity of HUCPC to integrate into the damaged
cell layer, secretion of the pro-surfactant protein C (Pro-C), a
marker of alveolar type II pneumocytes, was tested. Four distinct
proteins isolated from pulmonary surfactant are termed surfactant
proteins A, B, C and D, where the C protein is the mature form.
HUCPC did not express Pro-C both at the RNA (Fig. 4) and protein
levels before co-culture (Fig. 6A, I). Conversely, migratory HUCPC
co-expressed PKH26 and Pro-C, as assessed by immunocyto-
chemistry (Fig. 6B, V–VI). Moreover, these cells co-expressed
PKH26 together with CD146 and NG2 (Fig. 6B, VII–VIII).
At different co-culture times, supernatants were collected to
determine whether angiogenic factors were also secreted. HUCPC
in the presence of damage produced high levels of KGF and slight
modifications of VEGF levels during the whole culture (Fig. 7) in
comparison with the co-cultures with no damage. No PDGF-BB
was secreted.
Discussion
Perivascular cells have been recently identified in several human
tissues showing their stem cell properties. Schwab et al. [9]
Fig. 4 RT-PCR expression profile of
foetal HUCPC. RT-PCR was perfumed
with total RNA extracted from expanded
foetal HUCPC and the cDNA obtained
was used for PCR assays to evaluate the
expression of embryonic, myogenic,
endothelial and hematopoietic markers.
Negative controls (lane 1) were per-
formed with the reaction mix without the
cDNA. Positive controls (lane 2) were
obtained from the corresponding foetal
tissues. The samples of foetal HUCPC
used were at different passage of culture
(lane 3: passage 3; lane 4: passage 6).
Cultured foetal HUCPC were positive for
the embryonic markers Runx1 and Oct-
4, and for CD146. They were negative for
the expression of other embryonic
markers (Rex1, Sox-2), myogenic mark-
ers (MyoD, Myf5), endothelial markers
(CD31, CD34, CD144) and hematopoi-
etic markers (CD45, CD34).
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showed that human endometrium contains a small population of
perivascular cells that co-express CD146 and PDGF-R. Dellavalle
et al. [10] demonstrated that pericytes sorted from human skeletal
muscle by alkaline phosphatase expression can regenerate skeletal
myofibres in dystrophic immunodeficient mice. Even more
recently, Zanettino et al. [11] described a multipotent perivascular
cell population within adult human adipose tissue on the expres-
sion of stromal precursor antigen (STRO)-1 and 3G5. Extending
these previous observations, some of us validated the CD146
NG2 PDGF-R ALP CD34– CD45– vWF– CD144– phenotype as
an indicator of pericyte/perivascular cell identity throughout human
foetal and adult organs including muscle, pancreas, bone marrow,
adipose tissue and placenta [13]. Only Sarugaser et al. focused
their attention on the umbilical cord as a source of perivascular
cells, starting from full-term cord donors [12, 28].
Using as a marker the immunophenotype we recently validated
[13] to identify human perivascular cells, we set up to further
identify these cells within HUC and compare the frequency of
these cells within pre- and full-term cords. We confirmed the pres-
ence of perivascular cells around the large arteries and vein in full-
term cords, as already described by Sarugaser et al. [12].
Immunohistochemistry and, then, flow cytometry also showed
that, interestingly, small vessels typically surrounded by pericytes
are only present in foetal cords. The umbilical cord is formed by
the fusion of yolk sac derivatives and connecting stalk mes-
enchyme, and by weeks 12–14 contains tightly spiralled small
blood vessels. The higher frequency of pericyte-like cells we found
in pre-term cords is probably related to the transient presence of
these small vessels, which have disappeared at the end of gesta-
tion when the cord contains only two arteries and one vein [29].
These observations prompted us to isolate perivascular cells from
foetal cords, characterize these and document their multilineage
mesodermal potential. With a view to future therapeutic settings,
we also tested the ability of these cells to migrate towards an
injured tissue.
Since the umbilical cord is a well-known source of endothelial
cells [19, 20], we first developed a combined strategy of cell iso-
lation and cell culture to separate the perivascular cells. We
excluded any endothelial cell contamination: isolated perivascular
cells did not express any of the endothelial cell markers tested
including CD31, CD34 and CD144 by RT-PCR (Fig. 4), CD34,
CD133 and CD144 by flow cytometry (Fig. 3) and CD34, CD144,
CD133, vWF and Ulex europaeus receptor by immunofluorescence
(Table 3).
Moreover, the isolated perivascular cells were confirmed by
RT-PCR and flow cytometry not to include detectable hematopoi-
etic cells (CD34, CD45) or myogenic-like cells (CD56, MyoD,
Myf5) (Figs 3 and 4). The latter could have been brought from the
WJ since this gelatinous connective tissue contains cells with
ultrastructural characteristics of both fibroblasts and smooth
muscle cells [30]. In this regard, immunohistochemistry analysis
performed on foetal and full-term cords confirmed the presence of
genuine mesenchymal stromal cells in this region (Fig. 2B and D).
Moreover, HUCPC expressed SSEA-4, an early embryonic gly-
colipid antigen that is commonly used as a marker of human
embryonic stem cells and embryos at cleavage to blastocyst
stages, and which has been recently identified in the bone marrow
MSC population (Fig. 1D, IV) [31, 32]. SSEA-4 was co-expressed
with Oct-4, an embryonic cell marker arguably considered as an
indicator of stemness (Fig. 1D, V) [33, 34]. Interestingly, HUCPC
Fig. 5 (A) I: Alizarin red staining
showing area of mineralization on
HUCPC cultured in osteogenic differ-
entiating medium (magnification
20). (A) II: negative control. Slides
were acquired with Nikon Eclipse
TS100 equipped with a 20/040
Ph1 ADL. (B) I: Oil Red O staining
showing the accumulation of lipid
vacuoles in HUCPC after adipogenic
treatment (magnification 40). (B)
II: negative control. Slides were
acquired with Nikon Eclipse TS100
equipped with a 40/0.55 Ph1 ADL.
(C) Muscle differentiation after 21
days showed the typical myotubes
containing three to five nuclei and
co-expressing the tracking marker
PKH26 (red) and the human dys-
trophin (I) (green) and spectrin (II)
(green) (magnification 40). (C) III
and IV: negative controls. Slides
were analysed using a Video
Confocal Microscope (ViCo-Eclipse
80i, Nikon).
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co-expressed these embryonic cell markers together with perivas-
cular cell markers (Fig. 1D, IV) possibly as another indication of
the multipotency of pericytes.
Recently, some of us demonstrated that human perivascular
cells sorted from diverse human tissues and cultured over the
long term give rise to adherent, multi-lineage progenitor cells that
exhibit the features of MSC and concluded that pericytes are the
origin of that elusive stem cell population [13]. In the present
study, we also showed the expression of antigens that typify MSC
on cultured HUCPC at different passages (Fig. 3). To further doc-
ument a possible affiliation between HUCPC and MSC, we con-
firmed that cultured perivascular cells in appropriate inductive
conditions differentiate towards osteogenic (Fig. 5A, I), adipogenic
(Fig. 5B, I) and myogenic cell lineages (Fig. 5C, I and II).
Amongst all the stem cell populations isolated from different
tissues and with multipotency characteristics, HUCPC can be par-
ticularly appealing for therapeutic approaches because they pose
no ethical dilemmas. We focused our attention on foetal umbilical
cords because we envisioned an autologous application in prema-
ture infants who still remain at high risk for pulmonary morbidity
and mortality during the first 2 years of life, despite recent
improvement in perinatal care. In this regard, the survival of
extremely premature newborns has recently increased with the
use of new surfactant therapy and antenatal steroids [35].
Inflammatory damage to the airways and distal pulmonary tissue
of mechanically ventilated preterm infants might directly affect the
alveolar capillary unit and tissue integrity. The alveolus is com-
posed of two epithelial cell types with distinct morphologies. Type-
I cells comprise 95% of the alveolar surface and are important for
gas exchange, regulation of alveolar fluid levels and stretch-
induced modulation of surfactant secretion. Type-II cells are cru-
cial for producing surfactant and regulating alveolar fluid levels
and host defence. But notably they are also progenitors for type-I
cells during lung development and remodelling, thus the inability
Fig. 6 Foetal HUCPC migration assay. (A) Rat ATII cells, grown to 80% cell confluence in multiwell, were damaged exposing to bleomycin for 40 hrs.
After 24 hrs foetal HUCPC, negative for the pro-surfactant protein C (I) and stained with the red fluorescent dye PKH26, were co-cultured in transwells
in the presence of the damaged cell line. During 14 days of co-culture, foetal HUCPC migrate towards the rat ATII layer. Negative control was performed
with a non-damaged rat ATII cell line under the same culture conditions. (B) The migration was continuously evaluated with inverted fluorescence micro-
scope to observe the rat ATII cell line before the damage with bleomycin (I), after the damage (II), during the PKH26 foetal HUCPC migration (III: red)
and integration (IV: red). The migrated PKH26 foetal HUCPC (V: red) co-expressed the epithelial alveolar marker pro-surfactant protein C (VI: green).
Moreover, these cells maintain the expression of the perivascular markers CD146 (VII: green) and NG2 (VIII: green). All the cells (V–VIII) were stained
with DAPI (blue).
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of type-II cells to proliferate during the first week of life may per-
manently alter postnatal lung growth during a critical period of
postnatal lung development. This disruption in alveolar epithelial
cell differentiation might contribute to the pathological processes
seen in infants with chronic lung disease or BDP [36]. In this con-
text, we envisioned that HUCPC could represent a novel progeni-
tor for the cell therapy of lung disorders. In the last years, MSC
received much attention for their therapeutic potential in various
clinical settings of regenerative medicine notwithstanding when
tested in animal models of tissue damage they repair the injury
and restore the organ function despite the absence of obvious
integration and local differentiation in the host damaged tissue.
Therefore, other mechanisms should be envisioned to explain
these therapeutic results including paracrine effects. In this con-
text and since migration capacity is correlated with in vivo homing
and represents a predictor for the clinical outcome of cell-treated
patients [37], we set up a culture model of tissue damage to doc-
ument the migration of HUCPC and to evaluate if soluble factors
are secreted by them. We observed high levels of KGF and slight
modifications in VEGF levels in the co-culture of HUCPC in the
presence of damage in comparison with the control cultures, thus
indicating that perivascular cells can produce and secrete
cytokines that can play beneficial auto- or paracrine roles in tissue
repair. Moreover, we observed that conditioned medium contain-
ing soluble factors released by the damage has chemotactic
potential by itself. In particular, it is noteworthy that KGF plays a
critical role in lung development and that it is involved in prolifer-
ation, migration, and differentiation of epithelial cells in the skin,
cornea, intestines and distal airway [38]. KGF administration has
also been shown to protect the lung from a number of toxins
(hyperoxia, radiation and bleomycin exposure) [39, 40] and to
support the airway epithelium proliferation [41, 42] and differenti-
ation [41]. The secretory profile exhibited by foetal HUCPC in the
migration assay shows that via paracrine mechanisms they could
potentially limit the extension of injury (anti-apoptosis), inhibit
scarring and stimulate angiogenesis/vasculogenesis in a clinical
setting [43, 44].
In conclusion, given all these findings we demonstrated that
HUCPC represent a very promising source of multipotent cells
that, in addition to the current therapeutic modalities, could offer
an appealing cell-based approach that may have therapeutic
effects in various clinical settings including lung disorders.
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Fig. 7 ELISA assay was used
to investigate the presence of
soluble factors during the co-
culture of foetal PKH26
HUCPC with damaged (grey)
rat ATII cell line and without
damage (white). In black the
soluble factors released by
damaged ATII cell line.
Supernatants were collected
from six independent experi-
ments at different times during
the co-culture (24, 48, 72 hrs)
and the evaluated soluble fac-
tors were KGF, PDGF-BB and
VEGF. Data showed an
increase of KGF in the co-cul-
ture of HUCPC in the presence
of the damage (black) in com-
parison with non damage
(grey). KGF was statistically
significant at 48 and 72 hrs
(*P  0.05). The results are
expressed as mean  S.E.
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